APA (7th ed.) Citation

MD, H., BY, N., H, R., AA, C., DK, W., MPS, D., . . . M, D. (2020). Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(12), 2849. https://doi.org/10.1158/1078-0432.CCR-19-3418

Chicago Style (17th ed.) Citation

MD, Hellmann, et al. "Circulating Tumor DNA Analysis to Assess Risk of Progression After Long-term Response to PD-(L)1 Blockade in NSCLC." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26, no. 12 (2020): 2849. https://doi.org/10.1158/1078-0432.CCR-19-3418.

MLA (9th ed.) Citation

MD, Hellmann, et al. "Circulating Tumor DNA Analysis to Assess Risk of Progression After Long-term Response to PD-(L)1 Blockade in NSCLC." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 12, 2020, p. 2849, https://doi.org/10.1158/1078-0432.CCR-19-3418.